The 47th Annual Meeting of the Molecular Biology Society of Japan

Chairperson:Miho Sera(QIAGEN K.K.)

QIAGEN Ingenuity Pathway Analysis (IPA) supports the interpretation of your omics data by utilizing a high-quality knowledge base and a large amount of omics data from past research. This time, we will focus on the very hot field of chimeric antigen receptor (CAR) T cell therapy. CAR-T cell therapy is a promising treatment that aims to cure recurrent and refractory cancers, but the disease group in which it can provide sustained efficacy is still limited. Currently, research is being conducted to change the function of CAR-T cells. In order to make rational modifications to T cells, it is important to narrow down the process of finding key molecules related to functional decline such as terminal differentiation and exhaustion of T cells from comprehensive gene expression data such as RNA sequencing. By using IPA to search for upstream regulatory molecules that cause the comprehensive changes in RNA abundance, it may be possible to apply it to the rational improvement and development of CAR-T cells. In this presentation, we will introduce specific examples of CAR-T cell modifications that the presenter's group is promoting based on IPA interpretation.